Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Poseltinib - Hanmi Pharmaceutical

Next Previous
Drug Profile

Poseltinib - Hanmi Pharmaceutical

Alternative Names: HM 71224; LY 3337641; NB-02 - NOBO Medicine

Latest Information Update: 05 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hanmi Pharmaceutical
  • Developer Eli Lilly and Company; Hanmi Pharmaceutical; NOBO Medicine
  • Class Antineoplastics; Antirheumatics; Piperazines; Pyrimidines; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; BMX protein inhibitors; Emt protein-tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma; Lymphoma
  • Phase I Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 05 Aug 2026 Hanmi Pharmaceutical and NOBO Medicine have patents pending for combination therapy of poseltinib for preventing or treating lymphoma in South Korea and worldwide
  • 05 Aug 2026 Phase-I clinical trials in Diffuse large B cell lymphoma (Combination therapy, First-line therapy) (PO) before August 2026 (NOBO Medicine pipeline, August 2026)
  • 08 Dec 2025 Seoul National University Hospital plans a phase I/II Go-Pro-DLBCL trial for Diffuse-large-B-cell-lymphoma (Combination-therapy, Second-line or greater therapy) in South Korea (PO) in January 2026 (NCT07269639)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top